Quantification of intratumoral heterogeneity of HER2 status in breast cancer.

被引：0
|
作者：
Horii, Rie
Matsuura, Masaaki
Nitta, Hiro
Ito, Yoshinori
Ohno, Shinji
Iwase, Takuji
Akiyama, Futoshi
机构：
[1] Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Tokyo, Japan
[2] Japanese Fdn Canc Res, Inst Canc, Div Canc Genom, Tokyo, Japan
[3] Teikyo Univ, Grad Sch, Tokyo, Japan
[4] Ventana Med Syst Inc, Tucson, AZ USA
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Breast Oncol Ctr, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1036
引用
收藏
页数：5
相关论文
共 50 条
  • [41] HER2 status in bilateral breast cancer
    Crowe, Joseph P.
    Patrick, Rebecca J.
    Rybicki, Lisa A.
    Budd, G. Thomas
    Escobar, Pedro F.
    Tubbs, Raymond R.
    Hicks, David G.
    INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE, 2006, 51 (05) : 219 - 223
  • [42] Meta Analysis of Discordant HER2 Status in Matched Primary and Metastatic Breast Cancer.
    Richter, S.
    Zandvakili, A.
    CANCER RESEARCH, 2011, 71
  • [43] Clinical significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, in HER2-positive breast cancer
    Horii, R.
    Matsuura, M.
    Nitta, H.
    Maruyama, R.
    Ito, Y.
    Ueno, T.
    Iwase, T.
    Ohno, S.
    Akiyama, F.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S150 - S150
  • [44] The association between ATG4B and HER2 status in breast cancer.
    Bortnik, Svetlana
    Choutka, Courtney
    Horlings, Hugo
    Leung, Samuel
    Dragowska, Wieslawa
    Bally, Marcel
    Gelmon, Karen A.
    Nielsen, Torsten O.
    Gorski, Sharon
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] The discordance of the ER, PR, and HER2 status after neoadjuvant chemotherapy in breast cancer.
    Ustaalioglu, Basak Oven
    Bilici, Ahmet
    Aker, Fugen Vardar
    Erkol, Burcak
    Aliustaoglu, Mehmet
    Gurleyik, Gunay
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Changing ER, PgR, and HER2 status between primary and recurrent breast cancer.
    Matsumoto, Akiko
    Takahashi, Maiko
    Hayashida, Tetsu
    Hirose, Shigemichi
    Jinno, Hiromitsu
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [47] Intratumoral Heterogeneity of HER2 in Invasive Breast Carcinoma: How Much Testing Is Enough?
    Bethune, G. C.
    Chang, M. C.
    MODERN PATHOLOGY, 2013, 26 : 30A - 30A
  • [48] Intratumoral Heterogeneity of HER2 in Invasive Breast Carcinoma: How Much Testing Is Enough?
    Bethune, G. C.
    Chang, M. C.
    LABORATORY INVESTIGATION, 2013, 93 : 30A - 30A
  • [49] Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma
    Kondo, Yusuke
    Kikuchi, Tomoki
    Esteban, Joaquim Carreras
    Kumaki, Nobue
    Ogura, Go
    Inomoto, Chie
    Hirabayashi, Kenichi
    Kajiwara, Hiroshi
    Sakai, Akihiro
    Sugimoto, Ryousuke
    Otsuru, Mitsunobu
    Okami, Kenji
    Tsukinoki, Keiichi
    Nakamura, Naoya
    PATHOLOGY INTERNATIONAL, 2014, 64 (09) : 453 - 459
  • [50] Automatization of HER2 Status Assessment in Breast Cancer
    Makhov, Denis
    Samorodov, Andrey
    Slavnova, Elena
    2019 URAL SYMPOSIUM ON BIOMEDICAL ENGINEERING, RADIOELECTRONICS AND INFORMATION TECHNOLOGY (USBEREIT), 2019, : 171 - 173
12345